Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2018 2
2019 2
2020 11
2021 16
2022 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy in gynecological cancers.
Lorusso D, Ceni V, Daniele G, Pietragalla A, Salutari V, Muratore M, Nero C, Ciccarone F, Scambia G. Lorusso D, et al. Among authors: ciccarone f. Explor Target Antitumor Ther. 2021;2(1):48-64. doi: 10.37349/etat.2021.00033. Epub 2021 Feb 28. Explor Target Antitumor Ther. 2021. PMID: 36046088 Free PMC article. Review.
PTEN and Gynecological Cancers.
Nero C, Ciccarone F, Pietragalla A, Scambia G. Nero C, et al. Among authors: ciccarone f. Cancers (Basel). 2019 Sep 28;11(10):1458. doi: 10.3390/cancers11101458. Cancers (Basel). 2019. PMID: 31569439 Free PMC article. Review.
PARP Inhibitors Resistance: Mechanisms and Perspectives.
Giudice E, Gentile M, Salutari V, Ricci C, Musacchio L, Carbone MV, Ghizzoni V, Camarda F, Tronconi F, Nero C, Ciccarone F, Scambia G, Lorusso D. Giudice E, et al. Among authors: ciccarone f. Cancers (Basel). 2022 Mar 10;14(6):1420. doi: 10.3390/cancers14061420. Cancers (Basel). 2022. PMID: 35326571 Free PMC article. Review.
Integration of PARP-inhibitors in ovarian cancer therapy.
Pietragalla A, Ciccarone F, Nero C, Scambia G, Lorusso D, Daniele G. Pietragalla A, et al. Among authors: ciccarone f. Explor Target Antitumor Ther. 2020;1(3):171-182. doi: 10.37349/etat.2020.00011. Epub 2020 Jun 29. Explor Target Antitumor Ther. 2020. PMID: 36046198 Free PMC article. Review.
Newly diagnosed ovarian cancer: Which first-line treatment?
Lorusso D, Ceni V, Daniele G, Salutari V, Pietragalla A, Muratore M, Nero C, Ciccarone F, Scambia G. Lorusso D, et al. Among authors: ciccarone f. Cancer Treat Rev. 2020 Dec;91:102111. doi: 10.1016/j.ctrv.2020.102111. Epub 2020 Oct 9. Cancer Treat Rev. 2020. PMID: 33068886 Review.
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.
Lorusso D, Ceni V, Muratore M, Salutari V, Nero C, Pietragalla A, Ciccarone F, Carbone V, Daniele G, Scambia G. Lorusso D, et al. Among authors: ciccarone f. Expert Opin Emerg Drugs. 2020 Dec;25(4):445-453. doi: 10.1080/14728214.2020.1836155. Epub 2020 Oct 20. Expert Opin Emerg Drugs. 2020. PMID: 33040627 Review.
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer.
Pietragalla A, Duranti S, Daniele G, Nero C, Ciccarone F, Lorusso D, Fagotti A, Scambia G. Pietragalla A, et al. Among authors: ciccarone f. Expert Opin Investig Drugs. 2021 Feb;30(2):103-110. doi: 10.1080/13543784.2021.1868436. Epub 2021 Jan 11. Expert Opin Investig Drugs. 2021. PMID: 33423551 Review.
33 results